Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia.

Abstract

Iron-induced renal phosphate wasting, hypophosphataemia and osteomalacia have previously been reported in a small number of Japanese patients receiving parenteral iron sucrose. We report the case history of a European male who, as a result of regular intravenous iron polymaltose, developed prolonged hypophosphataemia complicated by widespread insufficiency fractures. The pathogenesis of this complication remains unknown however our novel finding of a marked elevation in fibroblast growth factor 23 (FGF23), which normalized after ceasing parenteral iron, suggests an important and previously unreported effect of iron on FGF23 homeostasis.

• Authors: Belinda J Schouten, Matthew P Doogue, Steven G Soule, Penelope J Hunt
• Journal: Annals of clinical biochemistry (Ann Clin Biochem) Vol. 46 Issue Pt 2 Pg. 167-9 (Mar 2009) ISSN: 0004-5632 [Print] England
• PMID: 19151167 (Publication Type: Case Reports, Journal Article)

Chemical References

• FGF23 protein, human
• Ferric Compounds
• Fibroblast Growth Factors
• Fibroblast Growth Factor-23
• teferrol

Topics

• Adult
• Ferric Compounds (adverse effects)
• Fibroblast Growth Factor-23
• Fibroblast Growth Factors (metabolism)
• Humans
• Hypophosphatemia (chemically induced)
• Infusions, Intravenous
• Male
• Osteomalacia (chemically induced)